Source: Acorda Therapeutics Press Release
Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing

FDA Assigns Priority Review and PDUFA Date of October 22, 2009
No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y., May. 6, 2009-Acorda Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009. The PDUFA date is the target date for the FDA to complete its review of the Fampridine-SR NDA.

“I am pleased that we were able to work quickly to address the comments from the FDA and resubmit our NDA approximately three weeks from having received the Refuse to File letter on our initial NDA submission, and that the FDA accepted the filing less than two weeks later,” said Ron Cohen, MD, Acorda Therapeutics’ President and CEO. “We are also encouraged that the FDA has elected to assign Priority Review status to the Fampridine-SR NDA.”

About Fampridine-SR
Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR is being developed by Acorda Therapeutics and manufactured by Elan Corporation plc.

For more information, please visit Acorda Therapeutic’s Web site at http://www.acorda.com/.

IN OTHER NEWS– Click here read about a study completed by Acorda and North American Research Committee on MS (NARCOMS) on the economic impact of early mobility impairment on people with MS.

This entry was posted on Friday, May 8th, 2009 at 9:20 am and is filed under News Alerts. You can follow any responses to this entry through the RSS 2.0 feed.